Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
greater disease » greater decrease (Expand Search), related disease (Expand Search), greater sense (Expand Search)
shape decrease » shape increases (Expand Search), small decrease (Expand Search), step decrease (Expand Search)
Showing 341 - 360 results of 24,497 for search '(( significant ((shape decrease) OR (greater disease)) ) OR ( significant decrease decrease ))', query time: 0.44s Refine Results
  1. 341
    Values of critical shape factor (<i>β</i>′) for different allowable relative deviations (<i>w</i><sub>2</sub>, in %).

    Values of critical shape factor (<i>β</i>′) for different allowable relative deviations (<i>w</i><sub>2</sub>, in %). by Hong Zhang (25820)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 342
    National (A) Medicare prescription rates per thousand Part D enrollees and (B) Medicare spending for clozapine gradually decreased for 2015-2020.

    National (A) Medicare prescription rates per thousand Part D enrollees and (B) Medicare spending for clozapine gradually decreased for 2015-2020. by Luke R. Cavanah (19022435)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 343
    Effects of finerenone on the UACR in all patients.

    Effects of finerenone on the UACR in all patients. by Jia Song (495396)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 344
    Changes in blood pressure, HbA1c, blood lipid and liver function-related indicator values compared with baseline values in all patients over time.

    Changes in blood pressure, HbA1c, blood lipid and liver function-related indicator values compared with baseline values in all patients over time. by Jia Song (495396)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 345
    Changes in blood pressure, HbA1c, blood lipids and liver function-related indicator values from 3 months to 6 months of treatment in all patients.

    Changes in blood pressure, HbA1c, blood lipids and liver function-related indicator values from 3 months to 6 months of treatment in all patients. by Jia Song (495396)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 346
    Changes in the UACR and urinary β2-MG levels compared with baseline values over time.

    Changes in the UACR and urinary β2-MG levels compared with baseline values over time. by Jia Song (495396)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 347
    Changes in the eGFRs and serum potassium levels compared with baseline values in all patients over time.

    Changes in the eGFRs and serum potassium levels compared with baseline values in all patients over time. by Jia Song (495396)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 348
    Comparison of the rates of decline in the UACR and urinary β2-MG levels between the two subgroups.

    Comparison of the rates of decline in the UACR and urinary β2-MG levels between the two subgroups. by Jia Song (495396)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 349
    Changes in the eGFRs and serum potassium levels compared with values at the end of 1 month of treatment in all patients over time.

    Changes in the eGFRs and serum potassium levels compared with values at the end of 1 month of treatment in all patients over time. by Jia Song (495396)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 350
    Changes in inflammatory cytokine levels compared with baseline values in all patients over time.

    Changes in inflammatory cytokine levels compared with baseline values in all patients over time. by Jia Song (495396)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 351
    Effects of finerenone on the urinary β2-MG levels in all patients.

    Effects of finerenone on the urinary β2-MG levels in all patients. by Jia Song (495396)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 352
    Baseline characteristics of the participants.

    Baseline characteristics of the participants. by Jia Song (495396)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 353
    Change in Watt’s Connectedness Scale, Subscales by Treatment Group.

    Change in Watt’s Connectedness Scale, Subscales by Treatment Group. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 354
    Primary and secondary efficacy end points (intention-to-treat population).

    Primary and secondary efficacy end points (intention-to-treat population). by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 355
    Demographic and clinical characteristics of participants at baseline.

    Demographic and clinical characteristics of participants at baseline. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 356
    Study-related adverse events.

    Study-related adverse events. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 357
    Study flow chart.

    Study flow chart. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 358
    Change in QIDS-SR-16 and MBI-HSS-MP by Treatment Group.

    Change in QIDS-SR-16 and MBI-HSS-MP by Treatment Group. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 359
    Study CONSORT diagram.

    Study CONSORT diagram. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 360
    Change in Demoralization Scale (DSII) by Treatment Group.

    Change in Demoralization Scale (DSII) by Treatment Group. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: